Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 6/20 | 0.42 |
| ▸ | RXRB | P28702 | 4/20 | 0.42 |
| ▸ | RXRG | P48443 | 4/20 | 0.42 |
| ▸ | CYP26B1 | Q9NR63 | 8/20 | 0.40 |
| ▸ | CYP26A1 | O43174 | 7/20 | 0.40 |
| ▸ | RARA | P10276 | 2/20 | 0.36 |
| ▸ | RARB | P10826 | 2/20 | 0.36 |
| ▸ | RARG | P13631 | 2/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13318274 | 0.94 | RXRA (0.42) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL1616186 | 0.86 | RXRA (0.53) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL14286010 | 0.84 | RXRA (0.42) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL3552820 | 0.75 | RXRA (0.41) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL7947551 | 0.74 | RXRA (0.46) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL3176733 | 0.73 | RXRA (0.54) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL11240978 | 0.73 | CYP26B1 (0.51) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL2090508 | 0.73 | ESR2 (0.42) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL2897524 | 0.70 | CYP26B1 (0.53) | RXRARXRBRXRGCYP26B1CYP26A1 | |
| SCHEMBL2090382 | 0.70 | ESR2 (0.40) | ESR1ESR2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003648-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003648-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003648-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7714008-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7714008-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7714008-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7687526-B2 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | AMGEN INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | AMGEN INC. (US) | 2008-04-17 | — | — | US | disclosed |
| WO-2008030618-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008030520-A1 | HETEROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008030520-A1 | HETEROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN ING. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN ING. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN ING. (US) | 2007-03-22 | — | — | US | disclosed |
| WO-2007033002-A1 | CONFORMATIONALLY CONSTRAINED 3- (4-HYDROXY-PHENYL) - SUBSTITUTED-PROPANOIC ACIDS USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007033002-A1 | CONFORMATIONALLY CONSTRAINED 3- (4-HYDROXY-PHENYL) - SUBSTITUTED-PROPANOIC ACIDS USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | PC, PNLIP, PDHX | RXRA 218/4885RXRB 447/4885RXRG 335/4885 |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | GPR119, GPR55, GPR65 | RXRA 338/4885RXRB 289/4885RXRG 213/4885 |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | GOT2, GLS2, PC | RXRA 150/4885RXRB 211/4885RXRG 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.